Summarized by Masters of Longevity from Longevity Technology.
Report on early human trial data showing a small-molecule NEK7 degrader reduced multiple inflammation biomarkers linked to atherosclerotic cardiovascular disease over four weeks.
Key Takeaways
- MRT-8102 produced median NEK7 reductions of about 80–90% across dose groups in the Phase 1 study.
- The drug lowered plaque-associated inflammatory markers, including calprotectin by 56% and SAA by 51% in high-baseline subjects.
- Subjects received once-daily oral doses for four weeks with an additional four-week follow-up period.
